Aceto to launch generic for ALS treatment

June 11, 2013

News

Article

Aceto Corporation, Port Washington, N.Y., announced June 11 that its generics subsidiary, Rising Pharmaceuticals Inc., Paramus, N.J., will launch the 50-mg strength of riluzole tablets.

Riluzole is used to treat amyotrophic lateral sclerosis (ALS) and in 2012 generated $64 million in sales, according to IMS Health. Aceto’s product is an FDA-approved version of Covis Pharma's (Switzerland) Rilutek. Rising Pharmaceuticals has launched nine generic products in 2013.

Related Content

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara

November 12th 2024

Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff

August 6th 2020

Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia

Lauren Biscaldi, MS, Managing Editor

November 5th 2024

Article

The drug is also approved to treat schizophrenia and bipolar depression.

FDA Approves Journey Medical’s Emrosi for Rosacea

Lauren Massaro

November 5th 2024

Article

“Emrosi has potential to become the best-in-class oral medication to treat the condition,” said the CEO of Journey Medical.

FDA Expands OA REMS, Mandates Mail-Back Envelopes for Opioid Analgesics

Lauren Massaro

November 4th 2024

Article

The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.